ClinicalTrials.gg
Not yet recruitingNCT07946731Epi_GDM_BUpdated Nov 18, 2026

Imprinting in Metabolic Diseases - Identifying Epigenetic Mechanisms in Human Gestational Diabetes Through Cell-free DNA - Part B

An observational study in Gestatiaonl Diabetes Mellitus, sponsored by University of Ulm. Not yet recruiting at 1 site in Germany. Open to female participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-18.

Sponsored by University of Ulm · Observational

Updated Nov 18, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Family-based
Time perspective
Prospective
Enrollment
15
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 13 studies in Diabetes, Gestational with a site in Germany — 7 open to participants now, 7 under way, none of them phase 3. Diabetes, Gestational · Germany.

Started
2027
the only one that year
Observational
6 of 13
4 open now
Registered
13th of 13
by date
Lead sponsor
3 of 13
University of Ulm

Among the 13 studies in Diabetes, Gestational with a site in Germany, this one is the only one that started in 2027, is one of 6 observational ones, and was the 13th registered.

Diabetes, Gestational

878 studies on the registry are indexed under Diabetes, Gestational; 198 are open to participants now.

Browse Diabetes, Gestational studies →

Open to participants now

7 of the 13 studies in Diabetes, Gestational with a site in Germany are open now. Recruiting first, the newest first:

1 more — sign in →

All 7 open studies →

A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →

Who these studies take

Of the 134 Diabetes, Gestational studies recruiting now, 62 (46%) set no upper age limit and 70 (52%) stop at 75 or younger; 13 take children under 18; 61 take healthy volunteers.

This study: 18 Years and older · female · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies in Diabetes, Gestational with a site in Germany, or all of them as a file.
02

Study summary

This clinical trial aims to investigate the development of and changes in fetal epigenetic signatures and how maternal metabolism influences these.

The metabolic profiles of the mother will be evaluated at three timepoints during pregnancy from a fasting blood sample and at another timepoints from an oral glucose tolerance test. Fetal epigenetic signatures can be identified by analyzing fetal cell-free DNA that circulates in the mother's bloodstream.

Read the detailed description

Maternal metabolism during pregnancy plays an important role in fetal development and may influence the establishment and development of epigenetic signatures in the fetus. Epigenetic modifications, such as DNA methylation, regulate gene expression and are involved in numerous developmental processes. Alterations in these epigenetic patterns during pregnancy may have long-term consequences for offspring health and susceptibility to metabolic diseases. In particular, maternal metabolic conditions, including gestational diabetes mellitus (GDM), may influence fetal epigenetic programming. However, the dynamic development of fetal epigenetic signatures throughout pregnancy and their relationship with maternal metabolic changes remain insufficiently understood.

Investigating the fetal epigenome during pregnancy has long been challenging due to the limited availability of fetal tissue and the risks associated with invasive sampling procedures. The discovery of fetal cell-free DNA (cfDNA) circulating in maternal blood provides a non-invasive opportunity to investigate fetal characteristics during pregnancy. Recent advances in cell-free DNA analysis have made it possible not only to detect fetal genetic information but also to characterize fetal epigenetic signatures.

The primary objective of this study is to investigate the development and changes in fetal epigenetic signatures throughout pregnancy and to assess how maternal metabolic profiles influence these signatures. In particular, the study aims to identify associations between maternal metabolic parameters and fetal epigenetic modifications and to explore potential changes in these associations over the course of pregnancy. Furthermore, the study seeks to identify fetal epigenetic signatures associated with [specific maternal metabolic conditions, e.g. gestational diabetes mellitus] and to explore their potential as biomarkers of maternal metabolic status and fetal development.

To address these objectives, maternal metabolic profiles will be assessed at three time points during pregnancy using fasting blood samples collected at 11+0-13+6, 19+0-24+0, and 28+0-34+0. Fetal health will be assessed via ultrasound measures at these timepoints. Maternal glucose metabolism will be characterized using an oral glucose tolerance test (OGTT) at 24+0-27+6. Fetal epigenetic signatures will be investigated by analyzing fetal cell-free DNA circulating in maternal blood samples collected at all four timepoints.

By combining longitudinal maternal metabolic assessments with the analysis of fetal epigenetic signatures, this study aims to provide new insights into the relationship between maternal metabolism and fetal epigenetic development during pregnancy. The findings may contribute to a better understanding of the mechanisms underlying fetal metabolic programming and the potential long-term consequences of altered maternal metabolism for offspring health.

03

Conditions studied

  • Gestatiaonl Diabetes Mellitus

Browse trials for

Keywords

  • epigenetics
  • pregnancy
  • cell-free DNA
  • metabolism
  • gestational diabetes
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Participants will be recruited from public advertisements posted at Ulm University as well as through cooperations with local gynecologists.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Pregnant women from gestational week 13+0
  • No known underlying medical conditions i
  • No known underlying diseases
  • Understanding and voluntary signing of a consent form before study- related examinations

Exclusion criteria

Exclusion Criteria:

  • Age \< 18 years
  • Type 1 or type 2 diabetes mellitus
  • Pharmacological treatment affecting blood glucose levels (e.g., , insulin)
  • Endocrine disorders (e.g., hyperthyroidism, polycystic ovary syndrome [PCOS])
  • Current depression or other psychiatric disorders
  • Eating disorders
  • Regular use of medication during pregnancy
  • Pre-existing cardiovascular disease
  • Drug and/or alcohol abuse
  • Estimated (eGFR) \< 60 ml/min/1.73 m²
  • C-reactive protein > 10 mg/l
  • Transaminase elevation of 2 times the upper norm
  • No consent to be informed about incidentally discovered pathological findings
  • Any other (clinical) condition that would endanger participants safety or question scientific success according to the physicians opinion.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Observational model
Family-based
Time perspective
Prospective
Enrollment
15 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • Pregnant women

    Metabolic and epigenetic characterization

    Other: Metabolic and epigenetic characterization of mothers and fetuses

Interventions

  • OtherMetabolic and epigenetic characterization of mothers and fetuses

    Maternal metabolic profiles will be assessed at three time points during pregnancy using fasting blood samples and at an additional time point using an oral glucose tolerance test (OGTT). Fetal epigenetic signatures will be investigated through the analysis of fetal cell-free DNA circulating in maternal blood. Fetal health will be assessed by ultrasound at the timepoints of the fasting blood samples No therapeutic intervention will be performed.

06

What researchers measure

Primary outcomes

  1. Epigenetic profiles of mothers and fetuses

    Methylation pattern of CpG sites in fathers, mothers and fetuses assessed from blood samples from the father and the mother. Genome-wide DNA methylation will be quantified as 5-methylcytosine (5mC) levels at CpG sites in maternal and paternal nuclear DNA from peripheral blood. Long-read sequencing will be used to detect genomic sequences and base modifications. Fetal DNA methylation will be assessed from fetal cell-free DNA isolated from maternal plasma using long-read sequencing. Allelic phasing will be applied to assign epigenetic modifications to parental origin. Deconvolution analysis will be used to subtract blood cell-derived epigenetic patterns and infer tissue-of-origin signals.

    Time frame: Gestational weeks 13+0 - 34+0

  2. Changes in epigenetic profiles of mothers and fetuses during pregnancy

    Changes in epigenetic profiles as determined in Primary Outcome 1 during pregnancy.

    Time frame: Gestational weeks 13+0 - 34+0

Secondary outcomes

  1. Epigenetic signatures of gestational diabetes

    Differentially methylated regions will be computed across parental genomic DNA and fetal cell-free DNA between women with and without gestational diabetes. Differentially methylated regions will be bioinformatically annotated to candidate genes and pathogenic pathways.

    Time frame: Gestational weeks 13+0 - 34+0

  2. Correlation of epigenetic signatures and glycemia

    Glucose level assessed from glucose measurements from fasting blood sample or oral glucose tolerance test.

    Time frame: Gestational weeks 13+0 - 34+0

  3. Correlation of epigenetic signatures with weight gain

    Correlation of changes in epigenetic signatures as assessed in primary outcome 2 with maternal weight gain.

    Time frame: Gestational weeks 13+0 - 34+0

  4. Correlation of epigenetic signatures and insulin sensitivity

    Insulin sensitivity assessed by Homeostasis Model Assessment of insulin resistance based on glucose and insulin measurements from fasting blood sample or oral glucose tolerance test.

    Time frame: Gestational weeks 13+0 - 34+0

  5. Correlation of epigenetic signatures and insulin secretion

    Insulin secretion assessed by Homeostasis Model Assessment of beta-cell function based on glucose and insulin measurements from fasting blood sample and oral glucose tolerance test.

    Time frame: Gestational weeks 13+0 - 34+0

  6. Correlation of epigenetic signatures and lipids

    Lipid profiles assessed from lipid measurements from fasting blood sample.

    Time frame: Gestational weeks 13+0 - 34+0

  7. Correlation of of epigenetic signatures with anthropometric features of the fetus

    Correlation of epigenetic signatures as assessed by primary outcome 1 with anthropometric features of the features assessed by ultrasound.

    Time frame: Gestational weeks 13+0 - 34+0

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jan 2027; primary completion for Dec 2028, 23 months later.

Of 142 non-industry observational studies under Diabetes, Gestational, half reached primary completion within 42 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 70. This study's planned 23 months is below that.

Counting every sponsor, half of 144 studies reached it within 42 months; a quarter within 19 and three quarters within 70.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 12, 2026
First posted
Nov 18, 2026
StartEst.
Jan 1, 2027
Primary completionEst.
Dec 31, 2028
CompletionEst.
Jun 30, 2029
Last update
Nov 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 18, 2026
Show all 1 update
  1. Nov 18, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07946731
Lead sponsor
University of Ulm
Responsible party
Martin Heni (Prof., University of Ulm) — Principal investigator
First posted
Nov 18, 2026
Start date
Jan 1, 2027 (estimated)
Primary completion
Dec 31, 2028 (estimated)
Completion
Jun 30, 2029 (estimated)
Last update
Nov 18, 2026

Study contacts

Martin Heni, Prof. MD
Contact
martin.heni@uniklinik-ulm.de
+49 731 500 44505
Sabrina Wangler, M.Sc.
Contact
sabrina.wangler@uniklinik-ulm.de
+49 731 500 44782

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion